Skip to main content
ITIJ

Main navigation

  • Latest
  • Magazine
  • Service Directory
  • Awards
  • Advertise
  • Subscribe

Secondary

  • Travel Insurance
  • Company News
  • Assistance & Repatriation
  • Air Ambulance
  • Travel
  • Health
  • Hospitals & Healthcare
  • Insurtech
  • General Insurance
  • Latest
  • Magazine
  • Service Directory
  • Awards
  • Advertise
  • Subscribe
  • Travel Insurance
  • Company News
  • Assistance & Repatriation
  • Air Ambulance
  • Travel
  • Health
  • Hospitals & Healthcare
  • Insurtech
  • General Insurance

Breadcrumb

  1. Home
  2. Latest
  3. Latest news
  4. Clinerion and Massive Bio partner to offer cancer patients access to innovative trials

Clinerion and Massive Bio partner to offer cancer patients access to innovative trials

Publishing Details

Hospitals & Healthcare

5 Dec 2019
Robyn Bainbridge

Share

partnership

A new partnership between patient-data harnessed patient network platform Clinerion and Massive Bio – provider of end-to-end patient enrollment services for oncology – aims to improve cancer patients’ access to leading-edge clinical trials

Keep on reading

Uruguay

New partnership enhances access to healthcare in Uruguay

A new partnership between Clinerion – a medical data informatics provider – and Eugen – a clinical development service provider based in Uruguay – will expand Clinerion’s Patient Network Explorer…
Read More

28 Nov 2019

Robyn Bainbridge

Via Clinerion’s service, the partnership offers Massive Bio access to oncology patient insights for site outreach and identification of cohorts for trial site selection and patient recruitment. Clinerion’s Patient Network Explorer – which covers 74 million patients in 19 countries around the world – queries anonymised patient data from its international network of partner hospitals to deliver real-world health data insights useful for Massive Bio’s site outreach programmes; while it’s ANID technology allows authorised clinical trial staff to re-identify patients for screening and inclusion in trials, speeding up patient recruitment.

Massive Bio, on the other hand, provides end-to-end patient enrollment technology and services in oncology clinical trials for patients treated at community practices. These services include patient identification/engagement, pre-screening, JIT (just in time) site activation, and real-world data services. In addition, Massive Bio provides value-based compensation to pharmaceutical companies by reducing time-to-market, complexity and costs in oncology clinical trial enrollment.

“With Clinerion’s market leadership outside the US and Massive Bio’s US market leadership in oncology clinical trials, we feel that we form a powerful combination to provide global coverage and serve a global client base which creates significant growth opportunities for both enterprises,” commented Selin Kurnaz, Co-Founder and CEO of Massive Bio. “We are excited for the opportunities in front of us.”

CEO of Clinerion Ian Rentsch noted that the partnership presented a new means of improving patient experience and outcomes. He added: “Massive Bio’s specialisation in oncology offers a great opportunity for Clinerion to support cancer patients in bringing them access to international clinical research and accelerate the development of next-generation medical interventions.”

Publishing Details

Hospitals & Healthcare

5 Dec 2019
Robyn Bainbridge

Share

Keep on reading

group business

HCA UK launches the International Services Group

Read More

22 Jan 2020

Robyn Bainbridge

Cleveland Clinic London

Cleveland Clinic to open innovative new facility in London

Read More

22 Jan 2020

Robyn Bainbridge

dementia patient

UK dementia patients ‘dumped and left’ in hospitals

Read More

23 Jan 2020

Robyn Bainbridge

Hubei

China erects hospital for coronavirus patients

Read More

24 Jan 2020

Robyn Bainbridge

ITIJ

Footer menu

  • About Us
  • Contact
  • Privacy Policy
  • Terms

Social

  • LinkedIn
  • Twitter
International Travel & Health Insurance Conferences

© Voyageur Publishing & Events 2022